<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00393458</url>
  </required_header>
  <id_info>
    <org_study_id>CQAB149B2334</org_study_id>
    <nct_id>NCT00393458</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control</brief_title>
  <official_title>A 52-week Treatment, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (300 and 600 µg Once Daily) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 µg Twice Daily) as an Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study was designed to assess the efficacy and long-term safety of 300 and 600 µg doses
      of indacaterol when delivered via a single-dose dry-powder inhaler (SDDPI) in patients with
      chronic obstructive pulmonary disease (COPD). Patients were randomized to receive either
      indacaterol 300 µg once daily, indacaterol 600 µg once daily, formoterol 12 µg twice daily,
      or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 + 1 Day, Day 85</measure>
    <time_frame>Week 12 + 1 day, Day 85</time_frame>
    <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days of Poor Control During 52 Weeks of Treatment</measure>
    <time_frame>Baseline to end of study (Week 52)</time_frame>
    <description>Percentage of days of poor control was defined as the number of days in the patient diary with a score ≥ 2 (scale of 0-3, a higher number means more severe symptoms) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness) over 52 weeks divided by the number of evaluable days (days with ≥ 2 symptoms with scores). The analysis included baseline percentage of days of poor control, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1732</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Indacaterol 300 μg plus placebo to formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indacaterol 600 μg plus placebo to formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol 12 μg plus placebo to indacaterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients inhaled formoterol 12 μg twice daily via the manufacturer's proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to indacaterol plus placebo to formoterol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol</intervention_name>
    <description>Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).</description>
    <arm_group_label>Indacaterol 300 μg plus placebo to formoterol</arm_group_label>
    <arm_group_label>Indacaterol 600 μg plus placebo to formoterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).</description>
    <arm_group_label>Formoterol 12 μg plus placebo to indacaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to indacaterol</intervention_name>
    <description>Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).</description>
    <arm_group_label>Formoterol 12 μg plus placebo to indacaterol</arm_group_label>
    <arm_group_label>Placebo to indacaterol plus placebo to formoterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to formoterol</intervention_name>
    <description>Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).</description>
    <arm_group_label>Indacaterol 300 μg plus placebo to formoterol</arm_group_label>
    <arm_group_label>Indacaterol 600 μg plus placebo to formoterol</arm_group_label>
    <arm_group_label>Placebo to indacaterol plus placebo to formoterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults ≥ 40 years, with a diagnosis of chronic obstructive pulmonary
             disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease
             (GOLD) guidelines 2005 and:

               1. Smoking history of at least 20 pack years

               2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) &lt; 80% and ≥ 30%
                  of the predicted normal value

               3. Post-bronchodilator FEV1/FVC (forced volume capacity) &lt; 70% (Post refers to
                  within 30 minutes after inhalation of 400 μg of salbutamol)

                  Exclusion Criteria:

          -  Patients who were hospitalized for a COPD exacerbation in the 6 weeks prior to
             screening.

          -  Patients who had a respiratory tract infection within 6 weeks prior to screening.

          -  Patients with concomitant pulmonary disease.

          -  Patients with a history of asthma.

          -  Patients with diabetes type I or uncontrolled diabetes type II.

          -  Any patient with lung cancer or a history of lung cancer.

          -  Patients with a history of certain cardiovascular co-morbid conditions.

        Other protocol-defined inclusion/exclusion criteria applied to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Investigator Site</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>San Miguel</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Rancagua</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Vina del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Cvikov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kyjov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ostrava Poruba</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tabor</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Zatec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Molleparkvej</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Guayaquil</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Quito</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Quito</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Beuvry</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Chamalieres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ferolles-Attilly</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Grasse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Marseilles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Montpellier Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Pessac Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bad Segeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bad Worishofen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Borstel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Forchheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Geesthacht</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Gelsenkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Grosshansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Gummersbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hagen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ilvesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Luebeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Luedenscheid</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Neumunster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Oschersleben</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ruedersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Schoenefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Strausberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Matrahaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Mosdos</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Petach-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kyunggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Uijeongbu-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Jekabpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Alytus</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Zutphen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Yekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Partizanske</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Begonte</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Caceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Mataro</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Petrel</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ponferrada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Locarno</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Munchenstein</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Zuerich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Yenisehir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bexhill-on-Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Chertsey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Slough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Ecuador</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2006</study_first_posted>
  <results_first_submitted>July 22, 2011</results_first_submitted>
  <results_first_submitted_qc>July 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2011</results_first_posted>
  <last_update_submitted>July 22, 2011</last_update_submitted>
  <last_update_submitted_qc>July 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <keyword>COPD</keyword>
  <keyword>indacaterol</keyword>
  <keyword>long-acting β2 agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Indacaterol 300 μg Plus Placebo to Formoterol</title>
          <description>Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="P2">
          <title>Indacaterol 600 μg Plus Placebo to Formoterol</title>
          <description>Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="P3">
          <title>Formoterol 12 μg Plus Placebo to Indacaterol</title>
          <description>Patients inhaled formoterol 12 μg twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="P4">
          <title>Placebo to Indacaterol Plus Placebo to Formoterol</title>
          <description>Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
                <participants group_id="P2" count="428"/>
                <participants group_id="P3" count="435"/>
                <participants group_id="P4" count="432"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed to Study Medication or Placebo</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
                <participants group_id="P2" count="425"/>
                <participants group_id="P3" count="434"/>
                <participants group_id="P4" count="432"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="338"/>
                <participants group_id="P2" count="326"/>
                <participants group_id="P3" count="323"/>
                <participants group_id="P4" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="112"/>
                <participants group_id="P4" count="137"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Indacaterol 300 μg Plus Placebo to Formoterol</title>
          <description>Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="B2">
          <title>Indacaterol 600 μg Plus Placebo to Formoterol</title>
          <description>Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="B3">
          <title>Formoterol 12 μg Plus Placebo to Indacaterol</title>
          <description>Patients inhaled formoterol 12 μg twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="B4">
          <title>Placebo to Indacaterol Plus Placebo to Formoterol</title>
          <description>Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="437"/>
            <count group_id="B2" value="425"/>
            <count group_id="B3" value="434"/>
            <count group_id="B4" value="432"/>
            <count group_id="B5" value="1728"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Demographic data are based on all subjects in the safety population, which includes all patients who received at least 1 dose of study drug. Three patients in the indacaterol 600 μg plus placebo to formoterol and one patient in the formoterol 12 μg plus placebo to indacaterol group were not exposed to any study treatment.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="8.57"/>
                    <measurement group_id="B2" value="62.9" spread="8.74"/>
                    <measurement group_id="B3" value="63.6" spread="8.49"/>
                    <measurement group_id="B4" value="63.2" spread="8.28"/>
                    <measurement group_id="B5" value="63.4" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                    <measurement group_id="B2" value="327"/>
                    <measurement group_id="B3" value="348"/>
                    <measurement group_id="B4" value="352"/>
                    <measurement group_id="B5" value="1378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 + 1 Day, Day 85</title>
        <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.</description>
        <time_frame>Week 12 + 1 day, Day 85</time_frame>
        <population>Modified intent-to-treat (ITT) population: All randomized patients who received at least 1 dose of study drug, excluding patients from a number of centers.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 300 μg Plus Placebo to Formoterol</title>
            <description>Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 600 μg Plus Placebo to Formoterol</title>
            <description>Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Formoterol 12 μg Plus Placebo to Indacaterol</title>
            <description>Patients inhaled formoterol 12 μg twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Indacaterol Plus Placebo to Formoterol</title>
            <description>Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 + 1 Day, Day 85</title>
          <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.</description>
          <population>Modified intent-to-treat (ITT) population: All randomized patients who received at least 1 dose of study drug, excluding patients from a number of centers.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="374"/>
                <count group_id="O3" value="379"/>
                <count group_id="O4" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.012"/>
                    <measurement group_id="O2" value="1.48" spread="0.013"/>
                    <measurement group_id="O3" value="1.38" spread="0.013"/>
                    <measurement group_id="O4" value="1.31" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days of Poor Control During 52 Weeks of Treatment</title>
        <description>Percentage of days of poor control was defined as the number of days in the patient diary with a score ≥ 2 (scale of 0-3, a higher number means more severe symptoms) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness) over 52 weeks divided by the number of evaluable days (days with ≥ 2 symptoms with scores). The analysis included baseline percentage of days of poor control, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.</description>
        <time_frame>Baseline to end of study (Week 52)</time_frame>
        <population>Modified intent-to-treat (ITT) population: All randomized patients who received at least 1 dose of study drug, excluding patients from a number of centers.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 300 μg Plus Placebo to Formoterol</title>
            <description>Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 600 μg Plus Placebo to Formoterol</title>
            <description>Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Formoterol 12 μg Plus Placebo to Indacaterol</title>
            <description>Patients inhaled formoterol 12 μg twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Indacaterol Plus Placebo to Formoterol</title>
            <description>Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days of Poor Control During 52 Weeks of Treatment</title>
          <description>Percentage of days of poor control was defined as the number of days in the patient diary with a score ≥ 2 (scale of 0-3, a higher number means more severe symptoms) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness) over 52 weeks divided by the number of evaluable days (days with ≥ 2 symptoms with scores). The analysis included baseline percentage of days of poor control, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.</description>
          <population>Modified intent-to-treat (ITT) population: All randomized patients who received at least 1 dose of study drug, excluding patients from a number of centers.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="377"/>
                <count group_id="O4" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="1.43"/>
                    <measurement group_id="O2" value="30.0" spread="1.46"/>
                    <measurement group_id="O3" value="33.5" spread="1.45"/>
                    <measurement group_id="O4" value="38.3" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety population: All patients who received at least 1 dose of study drug.</time_frame>
      <desc>Baseline to the end of the study (Week 52)</desc>
      <group_list>
        <group group_id="E1">
          <title>Indacaterol 300 μg Plus Placebo to Formoterol</title>
          <description>Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="E2">
          <title>Indacaterol 600 μg Plus Placebo to Formoterol</title>
          <description>Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="E3">
          <title>Formoterol 12 μg Plus Placebo to Indacaterol</title>
          <description>Patients inhaled formoterol 12 μg twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="E4">
          <title>Placebo to Indacaterol Plus Placebo to Formoterol</title>
          <description>Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer’s proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Microvascular angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior capsule contraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Colonoscopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Benign soft tissue neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the small bowel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Laryngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Tracheal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Obliterative bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoid operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="164" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="176" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="138" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="437"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

